TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04486833: Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Sponsor: Genprex, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 158 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$11,191,950

Rescue Site Savings

+$7,382,760

Unlock Full NCT04486833 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04486833 Rescue Dossier →